Journal of Neuro-Oncology

, Volume 99, Issue 1, pp 89–94

Up-front temozolomide in elderly patients with glioblastoma

  • Florence Laigle-Donadey
  • Dominique Figarella-Branger
  • Olivier Chinot
  • Luc Taillandier
  • Stéphanie Cartalat-Carel
  • Jérôme Honnorat
  • Gentian Kaloshi
  • Jean-Yves Delattre
  • Marc Sanson
Clinical Study - Patient Study

Abstract

Upfront temozolomide (TMZ) is often proposed for elderly patients with malignant gliomas as an alternative to radiotherapy (RT). A recent randomized trial showed that RT provides a survival benefit in elderly glioblastoma patients (≥70 years) with good performance status (KPS ≥ 70) compared with supportive care alone (median survival (MS) = 29.1 vs. 16.9 weeks). We retrospectively analyzed all patients who were eligible for this trial, but who refused to participate and were finally treated with TMZ alone. Thirty-nine eligible patients (median age: 75 years (range 70–83), median KPS: 70 (range 70–80), histologically proven glioblastomas) were treated up-front with oral TMZ for 1–12 cycles (mean = 5). One complete response and 10 partial responses were observed. Overall median survival (MS) was 36 weeks and median progression-free survival (PFS) was 20 weeks for the whole group. MS was 27.4 weeks and PFS was 19.5 weeks for the 27 patients that did not receive second-line treatment at progression. Eight grade III/IV toxicities (seven hematologic, one gastro-intestinal) were seen, but no treatment-related deaths were observed. These preliminary results support further randomized studies comparing TMZ with RT.

Keywords

Glioblastoma Elderly Chemotherapy 

References

  1. 1.
    Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre JY (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–1202CrossRefPubMedGoogle Scholar
  2. 2.
    Kita D, Ciernik IF, Vaccarella S, Franceschi S, Kleihues P, Lütolf UM, Ohgaki H (2009) Age as predictive factor in glioblastomas: population-based study. Neuroepidemiology 33:17–22CrossRefPubMedGoogle Scholar
  3. 3.
    Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648CrossRefPubMedGoogle Scholar
  4. 4.
    Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY (2007) Association of French-speaking neuro-oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535CrossRefPubMedGoogle Scholar
  5. 5.
    Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266CrossRefPubMedGoogle Scholar
  6. 6.
    Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM, Grisoli F (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214CrossRefPubMedGoogle Scholar
  7. 7.
    Chamberlain MC, Chalmers L (2007) A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol 82:207–209CrossRefPubMedGoogle Scholar
  8. 8.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  9. 9.
    Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385CrossRefPubMedGoogle Scholar
  10. 10.
    Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470–1475CrossRefPubMedGoogle Scholar
  11. 11.
    Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T (2003) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176–184PubMedCrossRefGoogle Scholar
  12. 12.
    Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173–179CrossRefPubMedGoogle Scholar
  13. 13.
    Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470–1475CrossRefPubMedGoogle Scholar
  14. 14.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588CrossRefPubMedGoogle Scholar
  15. 15.
    Idbaih A, Taillibert S, Simon JM, Psimaras D, Schneble HM, Lopez S, Lang P, Toubiana T, Feuvret L, Delattre JY, Mazeron JJ (2008) Short course of radiation therapy in elderly patients with glioblastoma multiforme. Cancer Radiother 12:788–792PubMedGoogle Scholar
  16. 16.
    Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMedGoogle Scholar
  17. 17.
    Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Florence Laigle-Donadey
    • 1
  • Dominique Figarella-Branger
    • 2
  • Olivier Chinot
    • 3
  • Luc Taillandier
    • 4
  • Stéphanie Cartalat-Carel
    • 5
  • Jérôme Honnorat
    • 5
  • Gentian Kaloshi
    • 1
  • Jean-Yves Delattre
    • 1
  • Marc Sanson
    • 1
  1. 1.Service de Neurologie MazarinHôpital de la SalpêtrièreParisFrance
  2. 2.Service d’Anatomo-PathologieHôpital de la TimoneMarseille Cedex 5France
  3. 3.Service d’OncologieHôpital de la TimoneMarseille Cedex 5France
  4. 4.Service de NeurologieHôpital CentralNancyFrance
  5. 5.Service de NeurologieHôpital Neurologique Pierre WertheimerLyon CedexFrance

Personalised recommendations